Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Common Equity (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Common Equity for 11 consecutive years, with $203.0 million as the latest value for Q4 2025.

  • Quarterly Common Equity changed N/A to $203.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $203.0 million through Dec 2025, changed N/A year-over-year, with the annual reading at $203.0 million for FY2025, N/A changed from the prior year.
  • Common Equity for Q4 2025 was $203.0 million at Crescent Biopharma, up from $116.6 million in the prior quarter.
  • The five-year high for Common Equity was $203.0 million in Q4 2025, with the low at -$30.2 million in Q1 2025.
  • Average Common Equity over 5 years is $68.9 million, with a median of $55.7 million recorded in 2022.
  • Peak annual rise in Common Equity hit 9058.6% in 2025, while the deepest fall reached 204.32% in 2025.
  • Over 5 years, Common Equity stood at $81.6 million in 2021, then tumbled by 47.39% to $42.9 million in 2022, then decreased by 10.52% to $38.4 million in 2023, then plummeted by 103.39% to -$1.3 million in 2024, then soared by 15692.32% to $203.0 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $203.0 million, $116.6 million, and $139.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.